{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cobicistat&page=2",
    "query": {
      "intervention": "Cobicistat",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cobicistat&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T19:46:02.169Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03782142",
      "title": "Effect on HIV Medications on EPC Cells",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AIDS"
      ],
      "interventions": [
        {
          "name": "Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Prezcobix",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sabyasachi Sen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "40 Years to 70 Years · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2018-11-01",
      "completion_date": "2021-12-14",
      "has_results": false,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782142"
    },
    {
      "nct_id": "NCT02993237",
      "title": "Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "DRV/COBI FDC placebo tablet",
          "type": "DRUG"
        },
        {
          "name": "D/C/F/TAF FDC placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-01-23",
      "completion_date": "2017-05-25",
      "has_results": false,
      "last_update_posted_date": "2019-05-13",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02993237"
    },
    {
      "nct_id": "NCT04388904",
      "title": "Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Crofoot Research Center, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2021-09-01",
      "completion_date": "2024-04-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04388904"
    },
    {
      "nct_id": "NCT02277600",
      "title": "A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "BMS-663068",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-11-05",
      "completion_date": "2015-01-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277600"
    },
    {
      "nct_id": "NCT01108510",
      "title": "Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "COBI",
          "type": "DRUG"
        },
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "COBI placebo",
          "type": "DRUG"
        },
        {
          "name": "RTV placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 698,
      "start_date": "2010-04",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-23",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01108510"
    },
    {
      "nct_id": "NCT03717129",
      "title": "Analysis of Crushed and Whole Tablet Genvoya",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Genvoya Oral dose",
          "type": "DRUG"
        },
        {
          "name": "Genvoya Crushed Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-04-15",
      "completion_date": "2021-11-01",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03717129"
    },
    {
      "nct_id": "NCT04040075",
      "title": "Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Biktarvy Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southampton Healthcare, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-07-01",
      "completion_date": "2022-07-08",
      "has_results": false,
      "last_update_posted_date": "2023-01-05",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04040075"
    },
    {
      "nct_id": "NCT02307656",
      "title": "Taste Properties of Atazanavir and Cobicistat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV in Adults"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Active Pharmaceutical Ingredient",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-12-12",
      "completion_date": "2021-09-09",
      "has_results": false,
      "last_update_posted_date": "2022-01-05",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 1,
      "location_summary": "Woburn, Massachusetts",
      "locations": [
        {
          "city": "Woburn",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307656"
    },
    {
      "nct_id": "NCT02603107",
      "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "DRV",
          "type": "DRUG"
        },
        {
          "name": "COBI",
          "type": "DRUG"
        },
        {
          "name": "ATV/co",
          "type": "DRUG"
        },
        {
          "name": "DRV/co",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 578,
      "start_date": "2015-11-20",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 63,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603107"
    },
    {
      "nct_id": "NCT02556268",
      "title": "Interaction With HIV Antiretroviral Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-DDI"
      ],
      "interventions": [
        {
          "name": "Riociguat (Adempas, BAY 63-2521)",
          "type": "DRUG"
        },
        {
          "name": "ATRIPLA",
          "type": "DRUG"
        },
        {
          "name": "COMPLERA",
          "type": "DRUG"
        },
        {
          "name": "STRIBILD",
          "type": "DRUG"
        },
        {
          "name": "TRIUMEQ",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral protease inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2016-02-23",
      "completion_date": "2016-12-07",
      "has_results": false,
      "last_update_posted_date": "2017-12-06",
      "last_synced_at": "2026-09-29T19:46:02.169Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556268"
    }
  ]
}